Brokers Offer Predictions for IPSC FY2029 Earnings

Century Therapeutics, Inc. (NASDAQ:IPSC) – Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for Century Therapeutics in a research note issued to investors on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the company will post earnings of ($1.18) per share for the year. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.63) per share.

Other equities research analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Century Therapeutics in a report on Wednesday, January 22nd. Guggenheim reaffirmed a “buy” rating on shares of Century Therapeutics in a report on Wednesday, January 22nd. Piper Sandler lowered their target price on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a report on Monday, December 30th. Finally, Chardan Capital lowered their target price on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $10.00.

Century Therapeutics Price Performance

Shares of Century Therapeutics stock opened at $0.77 on Friday. The firm has a market capitalization of $65.86 million, a PE ratio of -0.42 and a beta of 1.73. The company’s fifty day moving average price is $0.98 and its two-hundred day moving average price is $1.35. Century Therapeutics has a 52-week low of $0.68 and a 52-week high of $5.51.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC lifted its position in Century Therapeutics by 166.2% during the 4th quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock valued at $49,000 after purchasing an additional 29,992 shares during the period. Marshall Wace LLP acquired a new position in Century Therapeutics during the 4th quarter valued at about $36,000. XTX Topco Ltd acquired a new position in Century Therapeutics during the 4th quarter valued at about $87,000. Renaissance Technologies LLC lifted its position in Century Therapeutics by 146.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,202,885 shares of the company’s stock valued at $1,215,000 after purchasing an additional 714,685 shares during the period. Finally, Geode Capital Management LLC lifted its position in Century Therapeutics by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 991,595 shares of the company’s stock valued at $1,002,000 after purchasing an additional 23,413 shares during the period. Institutional investors and hedge funds own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.